Cidara Therapeutics (CDTX) said Monday that its phase 2b trial evaluating CD388, its long-acting antiviral for seasonal influenza prevention, met its primary and secondary endpoints.
The study showed that a single dose of CD388 provided 76.1% protection at 450 mg, 61.3% at 300 mg, and 57.7% at 150 mg against symptomatic influenza over 24 weeks.
CD388 was well tolerated with no adverse events observed, the company said.
Cidara said it has submitted an end-of-phase 2 meeting request to the US Food and Drug Administration to discuss plans for a phase 3 trial.
Cidara shares surged 83% in pre-market trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。